

Price Sensitive Information.

This is for information of all concerned that the Board of Directors of the Company in its 143rd Board Meeting held on 30th April, 2023, at 3:00 P.M. in the Conference Room at the Registered Office at 345 Segun Bagicha, Dhaka-1000, has approved the Third Quarter (Q3) Un-Audited Financial Statements of the Company for the period ended on 31st March, 2023, and disclosed the following financial indicators:

Particulars (Tk)		As at 31 March 2023		As at 30 June 2022	
i) Net Asset Value (NAV) (in lac)	:	2,915.28		3,083.52	
ii) Net Asset Value per Share (NAVPS)	:	93.44		98.83	
		01 July 2022 – 31 March 2023	01 July 2021 – 31 March 2022	01 January 2023 – 31 March 2023	01 January 2022 – 31 March 2022
iii) Net Profit After Tax (in lac)	:	1.68	477.79	(37.63)	144.41
iv) Earnings per Share (EPS)	:	0.05	15.31	(1.21)	4.63
v) Net Operating Cash Flow per Share (NOCFPS)	:	5.52	15.37	---	---
Reasons for significant deviations and the details of the Third Quarter (Q3) Un-Audited Financial Statements for the period ended on 31 st March 2023 are available in the website of the Company at www.pharmaaids.com					

Date: 30 April 2023

By the order of the Board
 Sd/-
 Faizul Hassan
 Managing Director